Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.40 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | CDK7 | P50613 | 1/20 | 0.40 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.40 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.40 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.40 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | SGK2 | Q9HBY8 | 1/20 | 0.40 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3195410 | 0.89 | FLT3 (0.47) | FLT3NPC1RAB9ASMN1; SMN2MET | |
| Hydrochloric Acid SCHEMBL3192624 | 0.83 | FGFR1 (0.47) | SMN1; SMN2TP53KDM4EALDH1A1HPGD | |
| SCHEMBL5697770 | 0.81 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL3183583 | 0.80 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL3206242 | 0.80 | BCHE (0.42) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL3193236 | 0.78 | GSK3B (0.55) | FLT3METCDK5DYRK3CDK1 | |
| SCHEMBL4061164 | 0.74 | DYRK3 (0.55) | FLT3CDK5DYRK3CDK1CDK2 | |
| SCHEMBL2130483 | 0.70 | CDK5 (0.55) | FLT3CDK5DYRK3CDK1CDK2 | |
| SCHEMBL2600366 | 0.70 | P4HA1 (0.44) | FLT3NPC1RAB9ACDK5DYRK3 | |
| SCHEMBL4065913 | 0.69 | MAPT (0.51) | FLT3CDK5CDK1CDK2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683067-B2 | 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (GSK-3) | ASTRAZENECA AB (SE) | 2010-03-23 | — | — | US | claimed |
| US-20080275041-A1 | 3-Heterocyclyl-Indole Derivatives as Inhibitors of Glycogen Synthase Kinase-3 (Gsk-3) | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | US | claimed |
| CN-1886397-A | 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (gsk-3) | ASTRAZENECA AB (SE) | 2006-12-27 | — | — | CN | claimed |
| US-7683067-B2 | 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (GSK-3) | ASTRAZENECA AB (SE) | 2010-03-23 | — | — | US | disclosed |
| US-20080275041-A1 | 3-Heterocyclyl-Indole Derivatives as Inhibitors of Glycogen Synthase Kinase-3 (Gsk-3) | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | US | disclosed |
| CN-1886397-A | 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (gsk-3) | ASTRAZENECA AB (SE) | 2006-12-27 | — | — | CN | disclosed |
| EP-1667990-A2 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005027823-A2 | 3-HETEROCYCLYL-INDOLE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) | ASTRAZENECA AB (SE) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275041-A1 | 3-Heterocyclyl-Indole Derivatives as Inhibitors of Glycogen Synthase Kinase-3 (Gsk-3) | GSK3B, GSK3A, GSKIP | FLT3 1020/4885NPC1 2093/4885RAB9A 3010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.